Dr. Raymond Schuch

Raymond Schuch, Ph.D.

Vice President of Research, ContraFect Corporation, USA

Raymond Schuch Ph.D. is the Vice President of Research at ContraFect Corporation in Yonkers, New York.  He earned his Bachelor of Science in Biology from the State University of New York at Binghamton and received his Ph.D. in molecular genetic from the Temple University School of Medicine.  During his doctorate he investigated the molecular genetics of bacterial spore formation, a cellular differentiation process used by micro-organisms, like Bacillus anthracis, to avoid starvation.  Between 1996 and 2000 Dr. Schuch was a post-doctoral fellow in the laboratory of Dr. Anthony Maurelli at the National Naval Medical Center studying the molecular pathogenesis of the Gram-negative  Shigella flexneri and related Gram-negative biowarfare agents.  His post-doctoral work focused on elucidating the architecture of the Type III virulence protein translocon, and determining the mechanism by which pathogens sense contact with human cells, invade the intracellular environment, and spread intercellularly.  In 2001, Dr. Schuch was offered a position as a Research Assistant Professor in the laboratory of Dr. Vincent Fischetti at The Rockefeller University. In Dr. Fischetti’s lab he started the molecular and genetic characterization of bacteriophage lysins used to detect and treat human pathogenic bacteria. He developed a series of targeted and metagenomic screens for highly active lysins, identified and characterized library of enzymes, using a series of in vitro assays and murine infection models. His work contributed to define the hallmark phenotypes of lysins – rapid and specific kill, anti-biofilm activity, absence of resistance, and potent synergy with antibiotics, and resulted in many publications. In 2011, Dr. Schuch joined Contrafect Corporation to assist with his vast antimicrobial experience to the development of a state-of-the-art research facility aimed to move the lysin field into its next exciting phase – human clinical development.